title: Double down for a double win.
abstract: The rationale for using multiple inhibitors between and within the phosphoinositide 3-kinase/AKT/mTOR and RAS/MEK/ERK pathways is scientifically compelling, and a limited number of experimental agents are currently being tested in phase I combinations. Patient subpopulations, whose tumors are defined by genetic lesions, are showing promising responses to this approach.
authors.affiliation: Alternative Discovery and Development, GlaxoSmithKlein, King of Prussia, Pennsylvania 19406, USA. huangp@alum.mit.edu
authors.forename: Pearl S
authors.initials: PS
authors.lastname: Huang
mesh_terms: D005260:Female; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects*; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*